ReviewFrontiers in pharmacology2023
Phages against killer superbugs: An enticing strategy against antibiotics-resistant pathogens.
Review in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Bacteriocins as Alternative Antimicrobial Agents for Wound-Associated Infections: Mechanisms, Activity Against Biofilms and Translational Potential.Antibiotics (Basel, Switzerland) · 2026Review
- The gut reservoir of carbapenem-resistant Enterobacterales: from dysbiosis and colonization to infection and decolonization, with a focus on patients with hematologic malignancies - a narrative review.Frontiers in cellular and infection microbiology · 2026Review
- Frontiers in superbug management: innovating approaches to combat antimicrobial resistance.Archives of microbiology · 2025Review
- Engineering bacteriophages for targeted superbug eradication.Molecular biology reports · 2025Review
- Therapeutic and protective approaches to combatFrontiers in pharmacology · 2025Review
- A NovelCurrent issues in molecular biology · 2024Article
- Bacteriophage DNA induces an interrupted immune response during phage therapy in a chicken model.Nature communications · 2024Article
- Article
- Automating Predictive Phage Therapy Pharmacology.Antibiotics (Basel, Switzerland) · 2023Review
- Modulation of the Gut Microbiota to Control Antimicrobial Resistance (AMR)-A Narrative Review with a Focus on Faecal Microbiota Transplantation (FMT).Infectious disease reports · 2023Review
- Editorial: Phage therapy in infectious diseases of animals and humans.Frontiers in cellular and infection microbiology · 2023Article
- Editorial: Women in phage biology: 2022.Frontiers in microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emerging resistivity of antibiotic resistance superbugs desire the need to resolve the global problem of antibiotic resistance. Among several other methods currently being adopted, one possible solution may be the development of supplemental therapies for antibiotics. The use of the normal and advanced bactericidal properties of bacteriophages (bacteriophage therapy) may be one of the viable infection control options. It is evident, however, that the safe and regulated application of phage treatment will need extensive knowledge of the characteristics and behaviour of certain phage-bacterium systems. This mini review offers an overview of the potential for phage therapy as well as the constraints and obstacles it faces in becoming a commonly accepted infection management strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.